Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE (Details 1) (USD $)	3 Months Ended		12 Months Ended
FAIR VALUE (Details 1) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain on derivatives resulting from change in fair value	$ 288,251	$ (54,945)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance - Fair value	1,127,500	3,355,000	3,355,000
Gain on derivatives resulting from change in fair value	(88,000)		(2,227,500)
Ending balance - Fair value	$ 1,039,500		$ 1,127,500